| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
DIALOGUES IN ONCOLOGY |
a Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California, USA; b the Cancer Center at Century City Hospital, Los Angeles, California, USA
Correspondence: Anton J. Bilchik, M.D., Ph.D., F.A.C.S., John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, California 90404, USA. Telephone: 310-449-5206; Fax: 310-449-5261; e-mail: bilchika{at}jwci.org
Radiofrequency ablation (RFA) is increasingly used for the local destruction of unresectable hepatic malignancies. Relative contraindications include tumors in proximity to vital structures that may be injured by RFA and lesions whose size exceeds the ablation capabilities of the probe system employed. Given current technology, we believe that RFA should be cautiously utilized for lesions greater than 5 cm in diameter. Open (celiotomy) and laparoscopic approaches to RFA allow intraoperative ultrasonography, which may demonstrate occult hepatic disease. In addition, RFA performed via celiotomy can be accompanied by resection or cryosurgical ablation, and isolation of the liver from adjacent organs. Percutaneous RFA should be reserved for patients who cannot undergo general anesthesia, those with recurrent or progressive lesions, and those with smaller lesions sufficiently isolated from adjacent organs. Complications may be minimized when these approaches are selectively applied.
Related articles in The Oncologist:
This article has been cited by other articles:
![]() |
T. M. Pawlik, R. D. Schulick, and M. A. Choti Expanding Criteria for Resectability of Colorectal Liver Metastases Oncologist, January 1, 2008; 13(1): 51 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, J. Lin, T. Kanekura, J. Su, W. Lin, H. Xie, Y. Wu, J. Li, M. Chen, and J. Chang A Small Interfering CD147-Targeting RNA Inhibited the Proliferation, Invasiveness, and Metastatic Activity of Malignant Melanoma Cancer Res., December 1, 2006; 66(23): 11323 - 11330. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res., September 15, 2006; 66(18): 9134 - 9142. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in Atherogenesis Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1948 - 1957. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Nguyen, W. J. Scott, and M. Goldberg Radiofrequency ablation of lung malignancies. Ann. Thorac. Surg., July 1, 2006; 82(1): 365 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Pawlik, J.-N. Vauthey, E. K. Abdalla, R. E. Pollock, L. M. Ellis, and S. A. Curley Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver Arch Surg, June 1, 2006; 141(6): 537 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Sutherland, J. A. R. Williams, R. T. A. Padbury, D. C. Gotley, B. Stokes, and G. J. Maddern Radiofrequency ablation of liver tumors: a systematic review. Arch Surg, February 1, 2006; 141(2): 181 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Livraghi, L. Solbiati, M. F. Meloni, G. S. Gazelle, E. F. Halpern, and S. N. Goldberg Treatment of Focal Liver Tumors with Percutaneous Radio-frequency Ablation: Complications Encountered in a Multicenter Study Radiology, February 1, 2003; 226(2): 441 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.S. Langenhoff, W.J.G. Oyen, G.J. Jager, S.P. Strijk, Th. Wobbes, F.H.M. Corstens, and T.J.M. Ruers Efficacy of Fluorine-18-Deoxyglucose Positron Emission Tomography in Detecting Tumor Recurrence After Local Ablative Therapy for Liver Metastases: A Prospective Study J. Clin. Oncol., November 15, 2002; 20(22): 4453 - 4458. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Gabrilove Hematologic Malignancies: An Opportunity for Targeted Drug Therapy Oncologist, October 1, 2001; 6(2008): 1 - 3. [Full Text] [PDF] |
||||
![]() |
J. L. Gabrilove Angiogenic Growth Factors: Autocrine and Paracrine Regulation of Survival in Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 4 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.M. Pinedo and C.J. van Groeningen Emerging New Opportunities for Patients with Hepatic Metastases from Colorectal Cancer or Primary Hepatocellular Cancer Oncologist, February 1, 2001; 6(1): 12 - 13. [Full Text] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |